Neuroendocrine and Metabolic Disorder Solutions
Changing the Face of Oral Absorption Drugs
OUR PIONEERING LIP'RAL TECHNOLOGY ENABLES EFFICIENT ABSORPTION OF WATER INSOLUBLE DRUGS.
Our unique technology, coupled with our product development pipeline entails repositioning of established drugs with significantly improved patient compliance through an efficient 505(b)(2) regulatory pathway strategy. We are focused on metabolic and endocrine disorders such as:
- Liver Disease (NASH)
- Low Testosterone (Hypogonadism)
- Recurrent Pre-Term Birth
- Postpartum Depression
Press Releases
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor’s Cut Session
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the publication...
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results...